Reviewer's report 
 A National Survey on the Patterns of Treatment of Inflammatory Bowel Disease in Canada Title: 
Authors: 
Dr Robert J Hilsden ( rhilsden@ucalgary.ca )
Dr Marja J Verhoef ( mverhoef@ucalgary.ca )
Allan Best ( abest@vanhosp.bc.ca )
Gaia Pocobelli ( gpocobel@ucalgary.ca )
 2  26 May 2003 Version: Date: 
 Edward V Loftus Reviewer: 
 A paper whose findings are important to those with closely related research Level of interest: 
interests 
 Accept without revision Advice on publication: 
Dr Hilsden and colleagues have satisfactorily addressed my concerns. They have added sentences 
to the Discussion which point out that although this sample of patients is more representative of the IBD population than a sample from an individual clinic, it should not be construed as being 
representative of the Canadian IBD population as a whole (e.g., higher percentage of Crohn's 
disease patients than expected, high socioeconomic status, etc.). 
Competing interests: 
research support from GlaxoSmithKline, Schering-Plough, AstraZeneca, Procter and Gamble 
consultant for AstraZeneca 
Reviewer's report 
 A National Survey on the Patterns of Treatment of Inflammatory Bowel Disease in Canada Title: 
Authors: 
Dr Robert J Hilsden ( rhilsden@ucalgary.ca )
Dr Marja J Verhoef ( mverhoef@ucalgary.ca )
Allan Best ( abest@vanhosp.bc.ca )
Gaia Pocobelli ( gpocobel@ucalgary.ca )
 2  26 May 2003 Version: Date: 
 Edward V Loftus Reviewer: 
 A paper whose findings are important to those with closely related research Level of interest: 
interests 
 Accept without revision Advice on publication: 
Dr Hilsden and colleagues have satisfactorily addressed my concerns. They have added sentences 
to the Discussion which point out that although this sample of patients is more representative of the IBD population than a sample from an individual clinic, it should not be construed as being 
representative of the Canadian IBD population as a whole (e.g., higher percentage of Crohn's 
disease patients than expected, high socioeconomic status, etc.). 
Competing interests: 
research support from GlaxoSmithKline, Schering-Plough, AstraZeneca, Procter and Gamble 
consultant for AstraZeneca 
Please review this paper.
user
Reviewer's report 
 A National Survey on the Patterns of Treatment of Inflammatory Bowel Disease in Canada Title: 
Authors: 
Dr Robert J Hilsden ( rhilsden@ucalgary.ca )
Dr Marja J Verhoef ( mverhoef@ucalgary.ca )
Allan Best ( abest@vanhosp.bc.ca )
Gaia Pocobelli ( gpocobel@ucalgary.ca )
 2  26 May 2003 Version: Date: 
 Edward V Loftus Reviewer: 
 A paper whose findings are important to those with closely related research Level of interest: 
interests 
 Accept without revision Advice on publication: 
Dr Hilsden and colleagues have satisfactorily addressed my concerns. They have added sentences 
to the Discussion which point out that although this sample of patients is more representative of the IBD population than a sample from an individual clinic, it should not be construed as being 
representative of the Canadian IBD population as a whole (e.g., higher percentage of Crohn's 
disease patients than expected, high socioeconomic status, etc.). 
Competing interests: 
research support from GlaxoSmithKline, Schering-Plough, AstraZeneca, Procter and Gamble 
consultant for AstraZeneca 
assistant